Abstract
The prognosis of metastatic renal cell cancer (RCC) is poor due to the lack of an effective treatment. Continuous circadian infusion of FUDR (5-fluoro-deoxyuridine) by the implantable Synchromed-Medtronic infusion system achieves an effective response in 24% of cases. The association with interferon seems to increase response rate. The Authors report their preliminary experience in 5 patients with metastatic RCC treated with chronoinfusion of FUDR and interferon. All patients tolerated the treatment well and no major toxicity was observed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
